Wearable tech aims to monitor rare muscle disease

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Autoimmune MG with or without history of thymoma, MGFA severity Class IIa/b, IIIa/b or IVa/b at the screening visit * Diagnosed gMG through ONE of the following methods: * Positive acetylcholine receptor antibody (AChR Ab) test * Positive muscle specific kinase receptor antibody (MuSK Ab) test * Positive LRP4 antibody and abnormal neuromuscular transmission demonstrated by single-fiber electromyography (SFEMG) or repetitive nerve stimulation (RNS) OR has maintained a positive response to treatments such as AChE inhibitors, IVIG/PLEX, FcRn antagonists or C5 inhibitors * Abnormal neuromuscular transmission demonstrated by single-fiber electromyography (SFEMG) or repetitive nerve stimulation (RNS) OR has maintained a positive response to treatments such as AChE inhibitors, IVIG/PLEX, FcRn antagonists or C5 inhibitors. * Physically and cognitively able to provide informed consent and adhere to the protocol, as determined by the investigator's judgment * Ambulatory status defined as the ability to walk a distance of 10 meters independently, with or without the use of an assistive device * Male or female, between the ages of 18 years old and 80 years old * Speaks and reads English fluently Exclusion Criteria: * Inability to engage in activities that are essential for independent living, such as dressing, bathing, toileting, or eating independently. * Neurological or orthopedic problems independent of myasthenia which significantly affect gait and ADLs in the investigator's judgement. * Any significant medical, laboratory, or psychiatric condition that, in the judgment of the investigators, would potentially interfere with the ability to participate in the study. * Residence in long-term care centers or institutions, nursing facilities, skilled nursing facilities, or recipients of hospice care, or incarceration. * MGFA severity class I or V (MG crisis) * Pregnant women. * Concurrent participation in an interventional clinical trial (observational studies, biomarker studies and registries are acceptable)